Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU : State-of-the-Art and Potential Socio-Economic Impact in the EU. Ed.: European Commission.
8 Angebote vergleichen
| Preise | 2013 | 2018 | 2019 |
|---|---|---|---|
| Schnitt | € 54,18 | € 161,42 | € 54,00 |
| Nachfrage |
1
Symbolbild
Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU : State-of-the-Art and Potential Socio-Economic Impact in the EU. Ed.: European Commission. (2011)
~EN PBISBN: 9783843328579 bzw. 3843328579, vermutlich in Englisch, Dictus Publishing, Taschenbuch.
Lieferung aus: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, AHA-BUCH [61614070], Einbeck, Germany.
Gebraucht - Sehr gut sg - ungelesenes mängelexemplar, gestempelt, mit leichten lagerspuren - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. 180 pp. Englisch.
Von Händler/Antiquariat, AHA-BUCH [61614070], Einbeck, Germany.
Gebraucht - Sehr gut sg - ungelesenes mängelexemplar, gestempelt, mit leichten lagerspuren - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. 180 pp. Englisch.
2
Symbolbild
Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU : State-of-the-Art and Potential Socio-Economic Impact in the EU. Ed.: European Commission. (2011)
DE PBISBN: 9783843328579 bzw. 3843328579, in Deutsch, Dictus Publishing, Taschenbuch.
Lieferung aus: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, AHA-BUCH [61614070], Einbeck, Germany.
Gebraucht - Sehr gut SG - Ungelesenes Mängelexemplar, gestempelt, mit leichten Lagerspuren, Versand per Büchersendung - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. 180 pp. Englisch.
Von Händler/Antiquariat, AHA-BUCH [61614070], Einbeck, Germany.
Gebraucht - Sehr gut SG - Ungelesenes Mängelexemplar, gestempelt, mit leichten Lagerspuren, Versand per Büchersendung - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. 180 pp. Englisch.
3
Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU (2011)
~EN PB USISBN: 9783843328579 bzw. 3843328579, vermutlich in Englisch, 180 Seiten, Dictus Publishing, Taschenbuch, gebraucht.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, AHA-BUCH GmbH, [3757134].
Gebraucht - Sehr gut sg - ungelesenes mängelexemplar, gestempelt, mit leichten lagerspuren - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. -, 01.01.2011, Taschenbuch, leichte Gebrauchsspuren, 259g, 180, Internationaler Versand, offene Rechnung, Banküberweisung, Kreditkarte, PayPal, offene Rechnung (Vorkasse vorbehalten).
Von Händler/Antiquariat, AHA-BUCH GmbH, [3757134].
Gebraucht - Sehr gut sg - ungelesenes mängelexemplar, gestempelt, mit leichten lagerspuren - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. -, 01.01.2011, Taschenbuch, leichte Gebrauchsspuren, 259g, 180, Internationaler Versand, offene Rechnung, Banküberweisung, Kreditkarte, PayPal, offene Rechnung (Vorkasse vorbehalten).
4
Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU (2011)
DE PB USISBN: 9783843328579 bzw. 3843328579, in Deutsch, 180 Seiten, Dictus Publishing, Taschenbuch, gebraucht.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, AHA-BUCH GmbH, [3757134].
Gebraucht - Sehr gut SG - Ungelesenes Mängelexemplar, gestempelt, mit leichten Lagerspuren, Versand per Büchersendung - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. -, 01.01.2011, Taschenbuch, leichte Gebrauchsspuren, 259g, 180, Internationaler Versand, offene Rechnung, Banküberweisung, Kreditkarte, PayPal, offene Rechnung (Vorkasse vorbehalten).
Von Händler/Antiquariat, AHA-BUCH GmbH, [3757134].
Gebraucht - Sehr gut SG - Ungelesenes Mängelexemplar, gestempelt, mit leichten Lagerspuren, Versand per Büchersendung - It is often said that advances in pharmacogenetics (PGx) could positively impact the pharmaceutical and health care sectors facilitating drug development (i.e. better understanding of disease mechanism, improved drug safety and efficacy) and a system of personalized medical care. However, the high expectations surrounding the clinical application of PGx are still largely unmet. Thus its potential impact on health care and its socio-economic implications remain uncertain. To diminish some of these uncertainties, IPTS embarked on a prospective study of the field with a three-fold objective that included mapping the current R&D status (i.e. mapping key actors, trends and outputs of academic and industrial R&D activities in the field), assessing the clinical impact (in socio-economic terms) in four EU member states (Germany, Ireland, the Netherlands and the UK), using two case studies (HER-2 and TPMT testing), and finally a comparison of regulatory and quality assurance frameworks in the US, the EU and the four EU member states mentioned above. -, 01.01.2011, Taschenbuch, leichte Gebrauchsspuren, 259g, 180, Internationaler Versand, offene Rechnung, Banküberweisung, Kreditkarte, PayPal, offene Rechnung (Vorkasse vorbehalten).
5
Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU (2011)
EN PB NWISBN: 9783843328579 bzw. 3843328579, in Englisch, 180 Seiten, Commission, European, Dictus Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Auf Lager. Lieferung von Amazon, Versandkostenfrei.
Von Händler/Antiquariat, Amazon.de.
Dictus Publishing, Taschenbuch, Publiziert: 2011-03-30T00:00:01Z, Produktgruppe: Book.
Von Händler/Antiquariat, Amazon.de.
Dictus Publishing, Taschenbuch, Publiziert: 2011-03-30T00:00:01Z, Produktgruppe: Book.
6
Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU (2011)
EN PB USISBN: 9783843328579 bzw. 3843328579, in Englisch, 180 Seiten, Dictus Publishing, Taschenbuch, gebraucht.
Lieferung aus: Deutschland, Gewöhnlich versandfertig in 24 Stunden, Versandkostenfrei. Tatsächliche Versandkosten können abweichen.
Von Händler/Antiquariat, buchrakete.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Von Händler/Antiquariat, buchrakete.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
7
Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU (2011)
EN PB NWISBN: 9783843328579 bzw. 3843328579, in Englisch, 180 Seiten, Dictus Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Gewöhnlich versandfertig in 24 Stunden, Versandkostenfrei.
Von Händler/Antiquariat, Amazon.de.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Von Händler/Antiquariat, Amazon.de.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…